ES2103301T3 - Acidos heterociclicos. - Google Patents

Acidos heterociclicos.

Info

Publication number
ES2103301T3
ES2103301T3 ES91308805T ES91308805T ES2103301T3 ES 2103301 T3 ES2103301 T3 ES 2103301T3 ES 91308805 T ES91308805 T ES 91308805T ES 91308805 T ES91308805 T ES 91308805T ES 2103301 T3 ES2103301 T3 ES 2103301T3
Authority
ES
Spain
Prior art keywords
square
group
sub
formula
tromboxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91308805T
Other languages
English (en)
Inventor
Alan Wellington Faull
Keith Russell
William John Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ES2103301T3 publication Critical patent/ES2103301T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION DESCRIBE NUEVOS DERIVADOS DE ACIDO 1, 3-DIOXANO ALQUENOICO DE LA FORMULA I DONDE: N ES EL ENTERO 1 O 2; Y ES METILENOXI, VINILENO O ETILENO; A ELEVADO 1 ES ALQUILENO (1-6C); R ELEVADO 1 ES UN GRUPO DE LA FORMULA R (AL CUADRADO) , A (AL CUADRADO) -, EN LA CUAL: R (AL CUADRADO) ES FENILO NO SUSTITUIDO O SOPORTANDO TRES SUSTITUYENTES QUE SE SELECCIONAN INDEPENDIENTEMENTE DE ALQUILO (1-6C), ALCOXI (1-6C), ALCANOILO (2-6C). ALQUITIO (1-6C), ALQUILSULFONILO (1-6C), HALOGENO, TRIFLUOROMETILO, NITRO Y CIANO; A (AL CUADRADO) ES UNA UNION DIRECTA A R (AL CUADRADO) O UN GRUPO DE LA FORMULA -W-C(R ELEVADO 4)(R ELEVADO 5) TA A R (AL CUADRADO) Y R ELEVADO 4 Y R ELEVADO 5 SON INDEPENDIENTEMENTE ALQUILO (1-4C); Q ES UN GRUPO HETEROCICLICO SELECCIONADO DE TIAZOL-5-IL Y IMIDAZOL-5-IL, ESTANDO EL ULTIMO NO SUSTITUIDO O SOPORTANDO UN GRUPO ALQUILO (1-12C) EN LA POSICION-1 DEL ANILLO DE IMIDIAZOLA; Y R ELEVADO 3 ES HIDROXI, UN RESIDUO DE ALCOHOL FISIOLOGICAMENTE ACEPTABLE, O ALCANOSULFONAMIDO (1-4C); O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES. LOS COMPUESTOS SON ANTAGONISTAS A SUB 2 DE TROMBOXANO E INHIBIDORES DE SINTASA A SUB 2 TROMBOXANA, Y SON UTILES PARA EL TRATAMIENTO DE UNA VARIEDAD DE ENFERMEDADES EN LA QUE ESTA INVOLUCRADA LA TROMBOXANA A SUB 2, TAL COMO LAS ENFERMEDADES DE CORAZON ISQUEMICAS, ENFERMEDAD CEREBRO VASCULAR Y ENFERMEDAD VASCULAR PERIFERICA. LA INVENCION INCLUYE TAMBIEN PROCESOS PARA LA FABRICACION Y USO DE LOS COMPUESTOS, Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ES91308805T 1990-10-04 1991-09-26 Acidos heterociclicos. Expired - Lifetime ES2103301T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909021571A GB9021571D0 (en) 1990-10-04 1990-10-04 Heterocyclic acids

Publications (1)

Publication Number Publication Date
ES2103301T3 true ES2103301T3 (es) 1997-09-16

Family

ID=10683219

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91308805T Expired - Lifetime ES2103301T3 (es) 1990-10-04 1991-09-26 Acidos heterociclicos.

Country Status (19)

Country Link
US (2) US5219874A (es)
EP (1) EP0482771B1 (es)
JP (1) JPH04273871A (es)
KR (1) KR100191763B1 (es)
AT (1) ATE154603T1 (es)
AU (1) AU646493B2 (es)
CA (1) CA2052294A1 (es)
DE (1) DE69126593T2 (es)
DK (1) DK0482771T3 (es)
ES (1) ES2103301T3 (es)
FI (1) FI914621A7 (es)
GB (2) GB9021571D0 (es)
GR (1) GR3023804T3 (es)
IE (1) IE913111A1 (es)
IL (1) IL99441A (es)
NO (1) NO303781B1 (es)
NZ (1) NZ239698A (es)
PT (1) PT99153B (es)
ZA (1) ZA917066B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248780A (en) * 1988-02-16 1993-09-28 Imperial Chemical Industries, Plc Pyridyl substituted alkenoic acid derivatives
EP0796109A1 (en) * 1993-12-17 1997-09-24 The Ohio State University Antisense oligonucleotides to suppress eicosanoid formation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58150575A (ja) * 1982-03-04 1983-09-07 Chugai Pharmaceut Co Ltd 新規なプロスタグランジン誘導体
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
GB8330099D0 (en) * 1983-11-11 1983-12-21 Ici Plc Cycloalkane derivatives
GB8330094D0 (en) * 1983-11-11 1983-12-21 Ici Plc Diphenyl compounds
GB8330097D0 (en) * 1983-11-11 1983-12-21 Ici Plc Cyclic ethers
GB8330120D0 (en) * 1983-11-11 1983-12-21 Ici Plc Chemical process
GB8511891D0 (en) * 1985-05-10 1985-06-19 Ici Plc Alkenoic acids
GR861209B (en) * 1985-05-10 1986-08-29 Ici Plc Process for preparing novel alkene derivatives
HU198706B (en) * 1985-05-10 1989-11-28 Ici Plc Process for producing 1,3-dioxan-ethers and pharmaceutical compositions containing them
GB8511892D0 (en) * 1985-05-10 1985-06-19 Ici Plc Fluoralkane derivatives
GB8511895D0 (en) * 1985-05-10 1985-06-19 Ici Plc Heterocyclic compounds
GB8511894D0 (en) * 1985-05-10 1985-06-19 Ici Plc Phenol derivatives
GB8511890D0 (en) * 1985-05-10 1985-06-19 Ici Plc Benzene derivatives
GB8611174D0 (en) * 1986-05-08 1986-06-18 Ici Plc Amide derivatives
ES2017633B3 (es) * 1985-11-12 1991-03-01 Ici Plc Amido derivados.
GB8531892D0 (en) * 1985-12-30 1986-02-05 Ici Plc Carboxylic acids
GB8626296D0 (en) * 1986-11-04 1986-12-03 Ici Plc Therapeutic agents
GB8626297D0 (en) * 1986-11-04 1986-12-03 Ici Plc Pharmaceutical compositions
GB8709794D0 (en) * 1987-04-24 1987-05-28 Ici Plc Heterocyclic acids
GB8901201D0 (en) * 1988-02-16 1989-03-15 Ici Plc Pyridine derivatives
EP0346511A1 (en) * 1988-06-15 1989-12-20 Fujisawa Pharmaceutical Co., Ltd. Oxygen-containing hererocyclic compound, processes for their preparation and pharmaceutical compositions comprising them
GB8814340D0 (en) * 1988-06-16 1988-07-20 Ici Plc Process
IE81170B1 (en) * 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
IL95760A0 (en) * 1989-09-27 1992-05-25 Rhone Poulenc Sante Imidazole derivatives,their preparation and pharmaceutical compositions containing the same
KR910006904B1 (ko) * 1989-10-16 1991-09-10 한국과학기술연구원 새로운 에스테르 화합물 및 그의 제조방법

Also Published As

Publication number Publication date
DE69126593T2 (de) 1997-10-02
FI914621A0 (fi) 1991-10-02
PT99153B (pt) 1999-04-30
EP0482771A2 (en) 1992-04-29
IE913111A1 (en) 1992-04-08
US5410064A (en) 1995-04-25
ZA917066B (en) 1992-06-24
EP0482771A3 (en) 1992-07-01
PT99153A (pt) 1992-09-30
FI914621A7 (fi) 1992-04-05
JPH04273871A (ja) 1992-09-30
IL99441A0 (en) 1992-08-18
GR3023804T3 (en) 1997-09-30
EP0482771B1 (en) 1997-06-18
KR920008022A (ko) 1992-05-27
IL99441A (en) 1996-12-05
NO303781B1 (no) 1998-08-31
AU646493B2 (en) 1994-02-24
KR100191763B1 (ko) 1999-06-15
NO913886L (no) 1992-04-06
DK0482771T3 (da) 1998-01-26
DE69126593D1 (de) 1997-07-24
NO913886D0 (no) 1991-10-03
AU8372791A (en) 1993-03-18
NZ239698A (en) 1994-03-25
ATE154603T1 (de) 1997-07-15
CA2052294A1 (en) 1992-04-05
GB9021571D0 (en) 1990-11-21
GB9118729D0 (en) 1991-10-16
US5219874A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
ES2152444T3 (es) Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos.
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
ES2038190T3 (es) Ester morfolinoetilico de acido micofenolico y derivados del mismo, su preparacion y uso en composiciones farmaceuticas.
ES2153098T3 (es) Derivados de quinazolina.
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
MX9300786A (es) Compuestos hipolipidaemicos.
UY28578A1 (es) Derivados de amida
AR009321A1 (es) Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen y compuestos intermediarios.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES2168487T3 (es) Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina.
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2160648T3 (es) Derivados de piridina.
ES2136677T3 (es) Derivados monomeros de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
ES8601994A1 (es) Un procedimiento para la preparacion de pirazolo-y piridazo-pirazolinas,-piridazinas y-diazepinas.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
DOP2023000221A (es) Inhibidores heteroaromáticos bicíclicos de la klk5
AR010984A1 (es) Nuevos esteres de la pleuromutilina, y el acido 1-azabiciclo-4- carbanilcarbanico; procedimiento para su preparacion y composicionesfarmaceuticas que los contienen.
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
ES2167021T3 (es) Derivados de acido 4-bifenil-4-hidroxibutirico sustituidos como inhibidores de metaloproteasa de matriz.
ES2055535T3 (es) Derivados de amina.
MX9205123A (es) Derivados de 5-hidroxi-2-pirimidinilmetileno utiles como agentes anti-inflamatorios.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 482771

Country of ref document: ES